Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. Donanemab was developed by Eli Lilly and Company. From Wikipedia
The expanding pipeline features diverse targets—from repurposed diabetes therapies to late-stage prevention studies—building on earlier antibody breakthroughs.
